Moreover, we found that the levels of both PTEN and p16 in CD34+/CD38−/CD82+ AML cells were lower than they were in CD34+/CD38−/CD82− AML cells (Fig 4D). This evidence concerns the gene CD38 and acute myeloid leukemia.